Garrido Serrano A, Guerrero Igea F J, Perianes Hernández C, Arenas Posadas F J, Palomo Gil S
Department of Gastrointestinal Medicine, Hospital Comarcal de Riotinto, Huelva, Spain.
Rev Esp Enferm Dig. 2002 Jul;94(7):395-405.
a) To analyse the probability of haemodynamic changes in patients with non-variceal upper gastrointestinal bleeding (NV-UGB), as well as the risk of bleeding in cases of peptic ulcer; and b) to compare an injection of epinephrine alone with epinephrine plus an sclerosing agent in ulcers with a high risk of persistent or recurrent bleeding.
We studied 500 consecutive patients (295 males/205 females) who were admitted because of an NV-UGB episode. Haemodynamic evaluation and upper endoscopy were performed in all patients. They were randomised to receive an injection of epinephrine 1:10.000 or epinephrine plus 2% polidocanol in case of active bleeding, visible vessel or unstable clot.
263/500 (52.6%) were taking NSAIDs before the acute bleeding. 70/96 (72.9%) patients with red haematemesis showed haemodynamic changes vs 15/107 (14%) with dark haematemesis and melena, and 29/281 (10.3%) with melena alone, p < 0.01, OR = 20. Duodenal ulcer was the cause of NV-UGB in 206 cases (40.6%) and gastric ulcer in 134 (27.2%). However, an endoscopic therapy was performed in 85 patients, 58 with gastric ulcers (19 with active bleeding, 33 with visible vessel and 6 with unstable clot) vs 27 with duodenal ulcers (6 with active bleeding, 19 with visible vessel and 2 with unstable clot), p < 0.01, OR = 4.7. 15/85 patients developed recurrent bleeding after injection therapy: 3 with a non-bleeding visible vessel and 10 with active bleeding (10 were treated with epinephrine and 2 with epinephrine plus 2% polidocanol, p < 0.04, OR = 8). A multivariate logistic regression analysis showed that age, active bleeding and type of injected agent were the only independent variables associated with failure of treatment and recurrent bleeding.
a) 52.6% of patients with NV-UGB were taking NSAIDs before acute bleeding; b) epinephrine injection followed by a sclerosing agent is more effective in case of active bleeding; however, there is no difference in case of visible vessel or unstable clot; and c) age, active bleeding and type of treatment were the only independent variables associated with recurrent bleeding.
a)分析非静脉曲张性上消化道出血(NV-UGB)患者血流动力学变化的可能性,以及消化性溃疡患者出血的风险;b)比较单纯注射肾上腺素与肾上腺素加硬化剂治疗持续性或复发性出血风险较高的溃疡的效果。
我们研究了500例因NV-UGB发作入院的连续患者(295例男性/205例女性)。对所有患者进行了血流动力学评估和上消化道内镜检查。对于活动性出血、可见血管或不稳定血凝块的患者,将他们随机分为接受1:10000肾上腺素注射或肾上腺素加2%聚多卡醇注射。
263/500(52.6%)的患者在急性出血前服用非甾体抗炎药(NSAIDs)。70/96(72.9%)的呕血患者出现血流动力学变化,而15/107(14%)的黑便和柏油样便患者以及29/281(10.3%)仅出现柏油样便的患者出现血流动力学变化,p<0.01,OR=20。十二指肠溃疡是206例(40.6%)NV-UGB的病因,胃溃疡是134例(27.2%)NV-UGB的病因。然而,85例患者接受了内镜治疗,58例胃溃疡患者(19例活动性出血、33例可见血管和6例不稳定血凝块),27例十二指肠溃疡患者(6例活动性出血、19例可见血管和2例不稳定血凝块),p<0.01,OR=4.7。15/85例患者在注射治疗后出现复发性出血:3例有非出血性可见血管,10例有活动性出血(10例用肾上腺素治疗,2例用肾上腺素加2%聚多卡醇治疗,p<0.04,OR=8)。多因素逻辑回归分析显示,年龄、活动性出血和注射药物类型是与治疗失败和复发性出血相关的仅有的独立变量。
a)52.6%的NV-UGB患者在急性出血前服用NSAIDs;b)在活动性出血时,注射肾上腺素后加用硬化剂更有效;然而,在可见血管或不稳定血凝块的情况下没有差异;c)年龄、活动性出血和治疗类型是与复发性出血相关的仅有的独立变量。